UNC
Unicycive Therap
Stock
Stock
ISIN: US90466Y1038
Ticker: UNCY
US90466Y1038
UNCY
Price
Price
CHART BY
Frequently asked questions
What is Unicycive Therap's market capitalization?
The market capitalization of Unicycive Therap is $71.00M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Unicycive Therap?
Unicycive Therap's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.797. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Unicycive Therap's stock?
Currently, 7 analysts cover Unicycive Therap's stock, with a consensus target price of $6.143. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Unicycive Therap?
Unicycive Therap's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$28.68M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Unicycive Therap?
Unicycive Therap has a free cash flow of -$26.52M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Unicycive Therap have, and what sector and industry does it belong to?
Unicycive Therap employs approximately 14 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Unicycive Therap's shares?
The free float of Unicycive Therap is 87.47M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $71.00M
- EPS (TTM)
- -$0.797
- Free Float
- 87.47M
- EBITDA (TTM)
- -$28.68M
- Free Cashflow (TTM)
- -$26.52M
Pricing
- 52W span
- $0.206$1.81
Analyst Ratings
The price target is $6.143 and the stock is covered by 7 analysts.
Buy
7
Hold
0
Sell
0
Information
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
- Employees
- 14
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US90466Y1038
- Primary Ticker
- UNCY